APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anlotinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anlotinib Market Outlook and Growth Opportunities 2026

Report ID 173964350423 December 2025199 pages

Choose your research edition.

Industry ResearchAnlotinib Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Anlotinib Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal Anlotinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anlotinib Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Anlotinib Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Anlotinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anlotinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anlotinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anlotinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anlotinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anlotinib market include CHIA TAI TIANQING. among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anlotinib market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anlotinib and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anlotinib revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anlotinib market.

Anlotinib Segment by Company

CHIA TAI TIANQING

Anlotinib Segment by Type

8mg Capsules

10mg Capsules

12mg Capsules

Anlotinib Segment by Application

Soft Tissue Sarcoma

Ovarian Cancer

Non-small Cell Lung Cancer

Others

Anlotinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anlotinib status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anlotinib key companies, revenue, market share, and recent developments.

3. To split the Anlotinib breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anlotinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anlotinib significant trends, drivers, influence factors in global and regions.

6. To analyze Anlotinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anlotinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anlotinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anlotinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anlotinib industry.

Chapter 3: Detailed analysis of Anlotinib company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anlotinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anlotinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anlotinib Industry Trends Table 2. Anlotinib Industry Drivers Table 3. Anlotinib Industry Opportunities and Challenges Table 4. Anlotinib Industry Restraints Table 5. Global Anlotinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anlotinib Revenue Share by Company (2021-2026) Table 7. Global Anlotinib Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anlotinib Key Company Manufacturing Base & Headquarters Table 9. Global Anlotinib Company, Product Type & Application Table 10. Global Anlotinib Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anlotinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 8mg Capsules Table 15. Significant Companies of 10mg Capsules Table 16. Significant Companies of 12mg Capsules Table 17. Global Anlotinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Anlotinib Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Anlotinib Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Anlotinib Sales Value Share by Type (2021-2026) Table 21. Global Anlotinib Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Soft Tissue Sarcoma Table 23. Significant Companies of Ovarian Cancer Table 24. Significant Companies of Non-small Cell Lung Cancer Table 25. Significant Companies of Others Table 26. Global Anlotinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Anlotinib Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Anlotinib Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Anlotinib Sales Value Share by Application (2021-2026) Table 30. Global Anlotinib Sales Value Share by Application (2027-2032) Table 31. Global Anlotinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Anlotinib Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Anlotinib Sales Value Share by Region (2021-2026) Table 34. Global Anlotinib Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Anlotinib Sales Value Share by Region (2027-2032) Table 36. Global Anlotinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Anlotinib Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Anlotinib Sales Value Market Share by Country (2021-2026) Table 39. Global Anlotinib Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Anlotinib Sales Value Market Share by Country (2027-2032) Table 41. CHIA TAI TIANQING Company Information Table 42. CHIA TAI TIANQING Business Overview Table 43. CHIA TAI TIANQING Anlotinib Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. CHIA TAI TIANQING Anlotinib Product Portfolio Table 45. CHIA TAI TIANQING Recent Development Table 46. Research Programs/Design for This Report Table 47. Authors List of This Report Table 48. Secondary Sources Table 49. Primary Sources List of Figures Figure 1. Anlotinib Product Image Figure 2. Global Anlotinib Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anlotinib Market Size (2021-2032) & (US$ Million) Figure 4. Global Anlotinib Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 8mg Capsules Image Figure 8. 10mg Capsules Image Figure 9. 12mg Capsules Image Figure 10. Global Anlotinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Anlotinib Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Anlotinib Sales Value Share by Type (2021-2032) Figure 13. Soft Tissue Sarcoma Image Figure 14. Ovarian Cancer Image Figure 15. Non-small Cell Lung Cancer Image Figure 16. Others Image Figure 17. Global Anlotinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Anlotinib Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Anlotinib Sales Value Share by Application (2021-2032) Figure 20. Global Anlotinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Anlotinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Anlotinib Sales Value (2021-2032) & (US$ Million) Figure 23. North America Anlotinib Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Anlotinib Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Anlotinib Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Anlotinib Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Anlotinib Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Anlotinib Sales Value (2021-2032) & (US$ Million) Figure 29. South America Anlotinib Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Anlotinib Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Anlotinib Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Anlotinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Anlotinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Anlotinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • 8mg Capsules
  • 10mg Capsules
  • 12mg Capsules
Applications
  • Soft Tissue Sarcoma
  • Ovarian Cancer
  • Non-small Cell Lung Cancer
  • Others
Companies covered
  • CHIA TAI TIANQING

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anlotinib Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anlotinib Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anlotinib Market Dynamics
  1. 2.1 Anlotinib Industry Trends
  2. 2.2 Anlotinib Industry Drivers
  3. 2.3 Anlotinib Industry Opportunities and Challenges
  4. 2.4 Anlotinib Industry Restraints
3 Anlotinib Market by Company
  1. 3.1 Global Anlotinib Company Revenue Ranking in 2025
  2. 3.2 Global Anlotinib Revenue by Company (2021-2026)
  3. 3.3 Global Anlotinib Company Ranking (2024-2026)
  4. 3.4 Global Anlotinib Company Manufacturing Base and Headquarters
  5. 3.5 Global Anlotinib Company Product Type and Application
  6. 3.6 Global Anlotinib Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anlotinib Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anlotinib Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anlotinib Market by Type
  1. 4.1 Anlotinib Type Introduction
  2. 4.1.1 8mg Capsules
  3. 4.1.2 10mg Capsules
  4. 4.1.3 12mg Capsules
  5. 4.2 Global Anlotinib Sales Value by Type
  6. 4.2.1 Global Anlotinib Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Anlotinib Sales Value by Type (2021-2032)
  8. 4.2.3 Global Anlotinib Sales Value Share by Type (2021-2032)
5 Anlotinib Market by Application
  1. 5.1 Anlotinib Application Introduction
  2. 5.1.1 Soft Tissue Sarcoma
  3. 5.1.2 Ovarian Cancer
  4. 5.1.3 Non-small Cell Lung Cancer
  5. 5.1.4 Others
  6. 5.2 Global Anlotinib Sales Value by Application
  7. 5.2.1 Global Anlotinib Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anlotinib Sales Value by Application (2021-2032)
  9. 5.2.3 Global Anlotinib Sales Value Share by Application (2021-2032)
6 Anlotinib Regional Value Analysis
  1. 6.1 Global Anlotinib Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anlotinib Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anlotinib Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anlotinib Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anlotinib Sales Value (2021-2032)
  7. 6.3.2 North America Anlotinib Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anlotinib Sales Value (2021-2032)
  10. 6.4.2 Europe Anlotinib Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anlotinib Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anlotinib Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anlotinib Sales Value (2021-2032)
  16. 6.6.2 South America Anlotinib Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anlotinib Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anlotinib Sales Value Share by Country, 2025 VS 2032
7 Anlotinib Country-level Value Analysis
  1. 7.1 Global Anlotinib Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anlotinib Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anlotinib Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anlotinib Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anlotinib Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anlotinib Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anlotinib Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anlotinib Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anlotinib Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anlotinib Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anlotinib Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anlotinib Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anlotinib Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anlotinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anlotinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anlotinib Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anlotinib Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anlotinib Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anlotinib Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anlotinib Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anlotinib Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anlotinib Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anlotinib Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anlotinib Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anlotinib Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anlotinib Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anlotinib Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anlotinib Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anlotinib Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anlotinib Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anlotinib Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anlotinib Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anlotinib Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anlotinib Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anlotinib Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anlotinib Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anlotinib Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anlotinib Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anlotinib Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anlotinib Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anlotinib Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anlotinib Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anlotinib Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anlotinib Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anlotinib Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anlotinib Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anlotinib Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anlotinib Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anlotinib Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anlotinib Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anlotinib Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anlotinib Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anlotinib Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anlotinib Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anlotinib Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anlotinib Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anlotinib Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anlotinib Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anlotinib Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anlotinib Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anlotinib Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anlotinib Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anlotinib Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anlotinib Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anlotinib Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anlotinib Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anlotinib Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anlotinib Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anlotinib Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anlotinib Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anlotinib Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anlotinib Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anlotinib Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anlotinib Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anlotinib Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anlotinib Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anlotinib Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anlotinib Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anlotinib Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anlotinib Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anlotinib Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anlotinib Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anlotinib Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anlotinib Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anlotinib Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anlotinib Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anlotinib Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anlotinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CHIA TAI TIANQING
  2. 8.1.1 CHIA TAI TIANQING Company Information
  3. 8.1.2 CHIA TAI TIANQING Business Overview
  4. 8.1.3 CHIA TAI TIANQING Anlotinib Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CHIA TAI TIANQING Anlotinib Product Portfolio
  6. 8.1.5 CHIA TAI TIANQING Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst